| Literature DB >> 23926885 |
Stephen C Teoh1, Andrew D Dick.
Abstract
Investigations used to aid diagnosis and prognosticate outcomes in ocular inflammatory disorders are based on techniques that have evolved over the last two centuries have dramatically evolved with the advances in molecular biological and imaging technology. Our improved understanding of basic biological processes of infective drives of innate immunity bridging the engagement of adaptive immunity have formed techniques to tailor and develop assays, and deliver targeted treatment options. Diagnostic techniques are paramount to distinguish infective from non-infective intraocular inflammatory disease, particularly in atypical cases. The advances have enabled our ability to multiplex assay small amount of specimen quantities of intraocular samples including aqueous, vitreous or small tissue samples. Nevertheless to achieve diagnosis, techniques often require a range of assays from traditional hypersensitivity reactions and microbe specific immunoglobulin analysis to modern molecular techniques and cytokine analysis. Such approaches capitalise on the advantages of each technique, thereby improving the sensitivity and specificity of diagnoses. This review article highlights the development of laboratory diagnostic techniques for intraocular inflammatory disorders now readily available to assist in accurate identification of infective agents and appropriation of appropriate therapies as well as formulating patient stratification alongside clinical diagnoses into disease groups for clinical trials.Entities:
Mesh:
Year: 2013 PMID: 23926885 PMCID: PMC3750647 DOI: 10.1186/1471-2415-13-41
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
An overview of validity of various tests (and combinations thereof) used in the diagnosis of infective uveitides
| Rubella (in FHI) | Aqueous IgG | 63 | 100.0% | [ | |
| Aqueous PCR | 20 | 10.0% | |||
| Rubella (in FHI) | GWC (> 3) | 14 | 71.4% | [ | |
| Aqueous PCR | 9 | 22.2% | |||
| Rubella (in FHI) | AI (≥ 1.5) | 52 | 100.0% | [ | |
| Aqueous PCR | 28 | 17.9% | |||
| TB | IGRA (T-SPOT.TB) | 162 | Sp 75.0%, Sen 36.0% | [ | |
| TST | | Sp 51.1%, Sen 72.0% | |||
| TST + T-SPOT.TB | | OR 2.16 (95% CI, 1.23-3.80) | |||
| HSV | PCR / GWC + | 13 | 46.2% | [ | |
| | GWC + | | 46.2% | ||
| VZV | PCR / GWC + | 16 | 62.5% | ||
| | GWC + | | 25.0% | ||
| Toxoplasma | PCR / GWC + | 25 | 28.0% | ||
| | GWC + | | 64.0% | ||
| Toxoplasma | GWC | 22-30 | 72.7%-93.3% | [ | |
| Toxoplasma | PCR + immunoblotting | 54 | Sen 73% | [ | |
| GWC + immunoblotting | | Sen 70% | |||
| PCR + GWC | | Sen 80% | |||
| PCR + GWC + immunoblotting | | Sen 85% | |||
| Toxoplasma | ELISA | 19 | Sp 85% | [ | |
| Immunoblotting | 19 | Sp 85% | |||
| PCR | 18 | Sp 100% | |||
| CMV, VZV, HSV, Toxoplasma | Multiplex PCR | 21 | 85.7% | [ | |
| Multiplex PCR | 71.4% (loss of <1 log sensitivity) |
*Most studies are cohort studies and do not represent robust outcomes of validation.
Values stated are positive rates of detection unless otherwise specified.
FHI Fuchs’ heterochromic iridocyclitis, GWC Goldmann-Witmer Coefficient, PCR polymerase chain reaction, AI antibody index, TB Tuberculosis, IGRA interferon-gamma release assays, TST tuberculin skin test, Sp specificity, Sen sensitivity, OR odds ratio, HSV herpes simplex virus, VZV varicella zoster virus.